PERCEPTIVE ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001224962

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 101 positions · Total reported value $5.20B · Top-10 concentration 53.5% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 65.6% · 18 new · 40 cut · 24 exited

Active Share (vs S&P 500): 99.3% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $6.30B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $5.20B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, PERCEPTIVE ADVISORS LLC disclosed 101 equity positions with a combined reported value of $5.20B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 53.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PRAX ($589.68M), SYRE ($309.04M), AMLX ($307.70M). By sector, the heaviest allocations are Health Care 94.4%, Industrials 1.8%. Versus the prior quarter, allocation shifted toward Health Care (+5.5pp), Industrials (+0.6pp) and away from Other (-5.9pp).

Versus the prior quarter, PERCEPTIVE ADVISORS LLC opened 18 new positions, trimmed 40 and fully exited 24, a turnover rate of 65.6% of positions. The portfolio's overlap with the prior quarter was 66% of names.

The largest new positions opened in Q3 2026 were WAT ($59.32M), IRD ($43.56M), LKFT ($36.84M).

Of the 24 positions fully exited versus the prior quarter, the largest were NUVL ($195.19M), APGE ($173.63M), IONS ($44.88M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • WAT WATERS CORP · $59.32M
  • IRD OPUS GENETICS INC · $43.56M
  • LKFT LAKEFRONT BIOTHERAPEUTICS NV · $36.84M
  • ABT ABBOTT LABORATORIES · $34.12M
  • MMED MINIMED GROUP INC · $25.70M
  • SEPN SEPTERNA INC · $22.21M
  • ELVN ENLIVEN THERAPEUTICS INC · $21.20M
  • DARE YARROW BIOSCIENCE INC · $18.31M

Fully Exited (vs previous quarter)

  • NUVL NUVALENT INC · prev qtr: $195.19M
  • APGE APOGEE THERAPEUTICS INC · prev qtr: $173.63M
  • IONS IONIS PHARMACEUTICALS INC · prev qtr: $44.88M
  • JAZZ JAZZ PHARMACEUTICALS PLC · prev qtr: $40.96M
  • SION SIONNA THERAPEUTICS INC · prev qtr: $39.81M
  • CORT CORCEPT THERAPEUTICS INC · prev qtr: $34.64M
  • CRL CHARLES RIV LABS INTL INC · prev qtr: $31.75M
  • AXSM AXSOME THERAPEUTICS INC. · prev qtr: $28.99M

Insider Transactions (Form 4)

Latest PERCEPTIVE ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-26 Opt exercise LeonaBio, Inc. 776,648 $0.00 SEC filing
2026-08-26 Buy Immatics N.V. 863,060 $8.69 SEC filing
2026-07-20 Award Freenome, Inc. 5,500,000 $10.00 SEC filing
2026-06-17 Award Kardigan, Inc. 20,706 — SEC filing
2026-04-17 Award MeiraGTx Holdings plc 555,555 $9.00 SEC filing

All insider transactions →

Fund Profile

Perceptive Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 101 US equity positions with a combined value of $5.20B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-71841 (status: Approved), registered 2010-10-04
  • Regulatory AUM (Form ADV): $11.77B as of 2026-07-13
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 17 private funds, of which 6 hedge funds

Portfolio Structure

  • 101 positions · $5.20B reported value (Q3 2026)
  • Top 10 holdings = 53.5% of reported value
  • Largest position: PRAX (PRAXIS PRECISION MEDICINES I) at 11.3%
  • Average position size: $51.53M

Sector Tilt

  • Health Care 94.4%
  • Industrials 1.8%
  • Financials 0.0%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q3 2026: 18 new, 15 added, 40 reduced, 24 exited
  • 28 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund reduced exposure to most top-10 holdings (8/10) but significantly increased positions in AMYLYX and Moderna, suggesting a selective bullish stance on biotech/healthcare, particularly in gene therapy and mRNA, while trimming broader biotech exposure. 2. Key moves: - Added: AMYLYX (+26.9% shares, weight surged 2.38%→5.91%), Moderna (+40.0% shares, weight surged 1.11%→5.18%). - Reduced: Praxis (-0.6% shares), Spyre (-2.7%), Rhythm (-2.1%), Roivant (-19.5%), Relay (-9.8%), Ascendis (-16.5%), Treverge (-5.6%), Edgewise (-5.4%). 3. Portfolio structure: Active, concentrated (101 positions), heavily biased toward Health Care (100% of top-10), with high risk appetite (volatile biotech stocks). 4. Per-holding one-liner: - PRAX: Biopharma (unverified), SYRE: Biotech (unverified), AMLX: Neurodegenerative drug developer (unverified), MRNA: mRNA vaccine/therapy (unverified), RYTM: Rare disease drugs (unverified), ROIV: Biotech (unverified), RLAY: Drug discovery (unverified), ASND: Growth disorders (unverified), TVTX: Rare diseases (unverified), EWTX: Brain tumor therapy (unverified). 5. Style summary: Selectively bullish on mRNA/gene therapy (AMLYX, MRNA) while trimming broader biotech exposure, reflecting a high-conviction, healthcare-focused active strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:40

Sector Allocation

Health Care 94.4%
Financials 0.0%
Other 3.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.02M $589.68M 11.33%
11.33%
Reduce
2 4.20M $309.04M 5.94%
5.94%
Reduce
3 10.57M $307.70M 5.91%
5.91%
Add
4 1.40M $269.60M 5.18%
5.18%
Add
5 2.53M $241.14M 4.63%
4.63%
Reduce
6 6.51M $238.11M 4.58%
4.58%
Reduce
7 12.73M $229.78M 4.42%
4.42%
Reduce
8 971.52K $221.34M 4.25%
4.25%
Reduce
9 3.54M $208.61M 4.01%
4.01%
Reduce
10 4.14M $168.01M 3.23%
3.23%
Reduce
11 1.29M $129.35M 2.48%
2.48%
Hold
12 5.37M $127.36M 2.45%
2.45%
Add
13 8.20M $120.96M 2.32%
2.32%
Hold
14 10.79M $118.65M 2.28%
2.28%
Hold
15 836.58K $117.87M 2.27%
2.27%
Reduce
16 11.25M $98.74M 1.90%
1.90%
Add
17 3.55M $93.92M 1.80%
1.80%
Reduce
18 1.07M $89.32M 1.72%
1.72%
Reduce
19 433.10K $88.90M 1.71%
1.71%
Reduce
20 11.91M $86.09M 1.65%
1.65%
Hold
21 10.30M $85.81M 1.65%
1.65%
Hold
22 2.68M $76.22M 1.47%
1.47%
Hold
23 2.69M $67.19M 1.29%
1.29%
Reduce
24 135.00K $59.32M 1.14%
1.14%
New
25 272.46K $52.37M 1.01%
1.01%
Add
26 2.11M $48.20M 0.93%
0.93%
Add
27 1.76M $44.96M 0.86%
0.86%
Add
28 9.00M $43.56M 0.84%
0.84%
New
29 1.24M $36.84M 0.71%
0.71%
New
30 345.23K $34.12M 0.66%
0.66%
New
31 200.00K $31.54M 0.61%
0.61%
Reduce
32 5.04M $31.33M 0.60%
0.60%
Hold
33 2.50M $30.77M 0.59%
0.59%
Add
34 2.51M $28.92M 0.56%
0.56%
Reduce
35 3.43M $26.62M 0.51%
0.51%
Hold
36 1.66M $26.57M 0.51%
0.51%
Reduce
37 1.32M $25.70M 0.49%
0.49%
New
38 9.27M $25.21M 0.48%
0.48%
Reduce
39 724.34K $24.34M 0.47%
0.47%
Reduce
40 567.48K $22.21M 0.43%
0.43%
New
41 7.35M $21.32M 0.41%
0.41%
Reduce
42 462.51K $21.20M 0.41%
0.41%
New
43 6.63M $21.01M 0.40%
0.40%
Hold
44 1.27M $20.38M 0.39%
0.39%
Reduce
45 2.46M $19.67M 0.38%
0.38%
Hold
46 813.10K $18.31M 0.35%
0.35%
New
47 519.35K $17.54M 0.34%
0.34%
Reduce
48 11.56M $16.42M 0.32%
0.32%
Reduce
49 970.85K $15.64M 0.30%
0.30%
Reduce
50 600.00K $14.59M 0.28%
0.28%
Add

FAQ

What did PERCEPTIVE ADVISORS LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, PERCEPTIVE ADVISORS LLC reported 101 equity positions worth $5.20B in aggregate; its largest disclosed positions were PRAX ($589.68M), SYRE ($309.04M), AMLX ($307.70M).

How large is PERCEPTIVE ADVISORS LLC's portfolio?

PERCEPTIVE ADVISORS LLC reported $5.20B of long equity holdings across 101 positions as of 2026-Q3. Top-10 holdings account for 53.5% of reported value.

What is PERCEPTIVE ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/perceptive-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →